RecruitingPhase 3NCT04168099
Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Comparative Study Between the Efficacy of Oral Gemifloxacin and Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Sponsor
Tanta University
Enrollment
60 participants
Start Date
Dec 1, 2018
Study Type
INTERVENTIONAL
Summary
oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Patients with spontaneous bacterial peritonitis
Exclusion Criteria1
- secondary peritonitis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCefotaxime
Cefotaxime IV
DRUGGemifloxacin
Gemifloxacin oral
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04168099